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ABSTRACT 
The Mr 16,000 NH2-terminal fragment of human prolactin (16K hPRL) is a potent antiangiogenic factor 
inhibiting endothelial cell function in vitro and neovascularization in vivo. The present study was undertaken to 
test the ability of 16K hPRL to inhibit the growth of human HCT116 colon cancer cells transplanted s.c. into 
Rag1-/- mice. For this purpose, HCT116 cells were stably transfected with an expression vector encoding a 
peptide that included the signal peptide and first 139 amino acid residues of human prolactin (HCT11616K). 
Stable clones of HCT11616K cells secreted large amounts of biologically active 16K hPRL into the culture 
medium. Growth of HCT11616K cells in vitro was not different from wild-type HCT116 (HCT116wt) or vector-
transfected HCT116 (HCT116vector) cells. Addition of recombinant 16K hPRL had no effect on the proliferation 
of HCT116wt cells in vitro. Tumor growth of HCT11616K cells implanted into Rag1-/- mice was inhibited 63% in 
four separate experiments compared with tumors formed from HCT116wt or HCT116vector cells. Inhibition of 
tumor growth of HCT11616K cells was correlated with a decrease in microvascular density by 44%. These data 
demonstrate that biologically active 16K hPRL can be expressed and secreted from human colon cancer cells 
using a gene transfer approach and that production of 16K hPRL by these cells was capable of inhibiting tumor 
growth and neovascularization. These findings support the potential of 16K hPRL as a therapeutic agent for the 
treatment of colorectal cancer. 
The abbreviations used are: bFGF, basic fibroblast growth factor; VEGF, vascular endothelial growth factor; 
16K hPRL, 16 kilodalton NH2-terminal fragment of human prolactin; CAM, chorioallantoic membrane; Ragl, 
recombination activation gene 1 ; BBE, bovine brain capillary endothelial; BCS, bovine calf serum; PAI-1, 
plasminogen activator inhibitor 1; vWF, von Willebrand factor; PMB, polymyxin B 
 
INTRODUCTION 
Angiogenesis, the formation of new blood vessels from a preexisting endothelium, is an essential component of 
tumor growth (1). Increasing evidence supports the concept that angiogenesis is controlled both by stimulatory 
angiogenic factors and inhibitory antiangiogenic factors. Angiogenic factors include: bFGF3 (2), VEGF (3), and 
angiogenin (4). Known antiangiogenic factors include: the 16K hPRL (5, 6), thrombospondin (7), angiostatin (8), 
endostatin (9), and platelet factor 4 (10). It is the balance between angiogenic and antiangiogenic factors that 
determines endothelial quiescence or activation. Tumor progression appears to involve a proangiogenic 
component, which is essential for neovascularization of the tumor and may correlate with rapid tumor growth 
and metastasis (11). 
In colon cancer, as well as in other tumors, progression correlates with increased vascularity and VEGF 
expression. Vessel counts are greater in metastatic tumors than in nonmetastatic tumors (12), and the proportion 
and intensity of VEGF expression are associated with progression from a benign adenoma to colon cancer (13). 
Vessel counts were highest in tumors with high VEGF expression and greater in metastatic than nonmetastatic 
tumors (14). Increased VEGF expression in metastatic tumors correlated with expression of the VEGF receptor, 
KDR, in colon cancer (12). A causal relationship between VEGF expression and colon cancer growth and 
metastasis was established in animal models. Treatment with a monoclonal antibody against VEGF inhibited 
tumor growth by up to 90% of Ls Lim6 and FΓM7 human colon carcinoma cell lines implanted s.c. in athymic 
mice (15). An inhibitor of the KDR receptor, SU5416, inhibited liver metastases, microvessel formation, and 
increased tumor and endothelial cell apoptosis after intrasplenic injection of CT-26 colon cancer cells (16). 
Several antiangiogenic factors have been tested in their ability to inhibit tumor growth and metastasis in colon 
cancer animal models. The injection of the fumagillol (TNP-470) into nude mice inhibited the growth and 
metastasis to the liver of orthotopic implants of several human colon cancer cell lines (17, 18). Injection of 
platelet factor 4 fragments inhibited growth of HCT116 colon cancer cells implanted s.c. (19). Stable transfection 
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of SW620 colon cancer cells with an endostatin-expressing vector resulted in inhibition of tumor growth and 
metastasis to the liver (20). 
For this study, we asked whether 16K hPRL, a potent antiangiogenic factor in vitro, was capable of inhibiting 
tumor growth in vivo. 16K hPRL negatively regulates multiple cellular processes necessary for the development 
of new capillaries, i.e., it inhibits VEGF and bFGF-induced capillary endothelial cell growth (6), signaling (21, 
22), migration, and organization (6) and activates apoptosis (23). In addition, recombinant 16K hPRL inhibited 
development of capillaries in the chick CAM assay (6, 24) and corneal vasculogenesis model (25). The effects of 
16K hPRL are specific for nontransformed vascular endothelial cells and have not been observed in numerous 
other cell types, e.g., COS, HCT116, Y-1, HEK293, and BHK-21, and Ishikawa cells and human primary 
endometrial stromal cells (5, 23). The actions of 16K hPRL are mediated via a novel, high-affinity, saturable 
binding site, distinct from the PRL receptor, and found only on vascular endothelial cells (26). 
Taking into consideration that in vitro 16K hPRL inhibits activation of two angiogenic pathways, we undertook 
this study to determine the ability of 16K hPRL to inhibit the growth of HCT116 colon cancer cells transplanted 
s.c. into Rag1-/- mice, which are Ragl homozygous knockout mice. We show for the first time that 16K hPRL 
stably expressed by HCT116 cells reduces tumor growth in vivo. 
MATERIALS AND METHODS 
Reagents. Cell culture medium and supplements for HCT116 cells and BBE cells were purchased from Life 
Technologies, Inc. (Grand Island, NY) unless otherwise noted, and bovine fetal and calf serum were purchased 
from Hyclone (Logan, UT). bFGF was purchased from Promega Corp. (Madison, WI). [3H]Thymidine (6.7 
Ci/mmol) was purchased from NEN (Boston, MA). PMB sulfate and E-TOXATE, a kit for detection and 
semiquantification of endotoxin levels, were obtained from Sigma Chemical Co.-Aldrich (St. Louis, MO). 
Cell Culture. The human colon cancer cell line HCT116, used for expression of 16K hPRL, was purchased from 
the American Type Culture Collection (Rockville, MD) and grown in McCoy's 5A medium without tricine. The 
medium was supplemented with 10% (vol/vol) FCS and 100 units/ml penicillin and streptomycin. BBE cells 
used for testing the bioactivity of expressed 16K hPRL were isolated as described previously (27). BBE cells 
were cultured in low-glucose DMEM (DMEM H16), supplemented with 10% (vol/vol) BCS, 2 mM glutamine 
and antibiotics (100 units/ml penicillin, 100 units/ml streptomycin, and 2.5 µg/ml fungizone). Human 
recombinant bFGF was added to the cell medium at a concentration of 1 ng/ml every other day. Experiments 
were initiated from confluent cell cultures between passage 7 and 13. 
Construction of 16K hPRL Expression Vector. For expression of 16K hPRL in mammalian cells, a Kozak 
consensus sequence (GCCGCCACC) was inserted 5' to the translational start site of the full length PRL cDNA 
(28) including the signal peptide. To produce a peptide consisting of the signal peptide and the first 139 amino 
acids of human prolactin, codon 140 was replaced by a stop codon by site-directed mutagenesis (16K hPRL-139; 
Ref 6). Cysteine 58 (TGG) was replaced with serine (TCC) to avoid the formation of normative disulfide 
bridges. The rabbit β-globin intron (29) was inserted at the 5' end of the 16K hPRL cDNA, which was then 
subcloned into BamHI and HindIII sites of the pRc/CMV vector (Invitrogen, Carlsbad, CA). The construct was 
verified by sequencing. 
Stable Transfection of HCT116 Cells. HCT116 cells were plated at a density of 300,000 cells/10-cm tissue 
culture plate 1 day prior to transfection. Ten µg of pRC/CMV vector or vector containing the 16K hPRL insert 
were transfected into HCT116 cells by the calcium phosphate-DNA method. Calcium-DNA precipitates were 
left on the cells for 6 h, cells were then treated with 20% glycerol in unsupplemented medium for 2 min, after 
which 10% supplemented growth medium was added. Stably transfected cells were selected 72 h after 
transfection by neomycin resistance at a G418 sulfate (Life Technologies, Inc.) concentration of 0.3 mg/ml. 
G418-resistant colonies were cloned by limiting dilution, individual clones were grown to confluence, and 
conditioned medium was assayed for 16K hPRL expression by Western Blot analysis and RIA . 
RNA Extraction and Northern Analysis. Total cytoplasmic RNA was prepared by the guanidine thiocyanate 
extraction method and was purified by centrifugation through a CsCl solution. Ten µg of total RNA were then 
electrophoresed through 1.2% agarose-formaldehyde gel, transferred by capillary blotting onto a nylon-based 
membrane Hybond N (Amersham Pharmacia Biotech, Piscataway, NJ), and hybridized with 3×106 cpm of the 
32P randomly primed 16K hPRL cDNA fragment (Oligolabeling kit; Amersham Pharmacia Biotech, Piscataway, 
NJ). Hybridization was followed by low stringency washes in 2×SCC and 0.1% SDS at room temperature, 
followed by high stringency washes in 0.2×SCC and 0.1% SDS at 68°C Filters were then exposed for 6 to 24 h 
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at -70°C. 
Collection of Conditioned Medium and Western Blot Analysis. Conditioned medium from stably transfected, 
subconfluent HCT116 cells was collected 48 h after addition of the medium, centrifuged at 12,000 rpm for 15 
min at 4°C to remove cellular debris, filtered through 0.2 µm filters (Gelman Sciences, Ann Arbor, MI), and 
stored at -80°C Conditioned medium was analyzed by electrophoresis through 15% polyacrylamide gels, 
followed by semidry transfer onto polyvinylidene difluoride membranes (Immobilon P; Millipore, Bedford, MA) 
and Western blot analysis. Western blots were probed with either a polyclonal anti-PRL antibody (1:500; 
provided by Genzyme) or a polyclonal anti-16K hPRL antibody (1:100; J. Martial, Liege, Belgium). Antigen-
antibody complexes were visualized by using l:10,000-diluted goat antirabbit antiserum (Amersham) coupled to 
horseradish peroxidase and ECL detection system (Amersham). 
RIA for 16K hPRL. Recombinant 16K hPRL was iodinated using a milder variation (30) of the chloramine T 
method (31). We used a rabbit anti-hPRL polyclonal antibody (Genzyme) that recognizes 16K hPRL as first 
antibody. Mouse and human PRL were not detected by this antibody. Bound from free complexes were 
precipitated with a goat antirabbit immunoglobulin antibody. The sensitivity of the assay was 10-20 ng/ml, and 
the intraassay coefficient of variation was 5-10%. 
BBE Cell Proliferation Assay by Determination of DNA Synthesis. DNA synthesis was assayed by 
measuring [3H]thymidine incorporation into trichloroacetic acid-insoluble material. BBE cells were plated for 24 
h at a density of 10,000 cells/well (six-well plates) in 1 ml of culture medium containing 10% BCS, serum-
starved for 24 h in 0.5% BCS in antibiotic and glutamine supplemented DMEM, and then incubated for 24 h 
with 50 pM bFGF in the presence of increasing amounts of conditioned medium from either HCT116wt, 
HCT116vector, or HCT11616K cells. Four h prior to harvesting, cells were pulsed with 500,000 cpm/well of 
[3H]thymidine (NEN). The reactions were terminated by addition of ice-cold 5% trichloroacetic acid for 20 min 
at 4°C, followed by three washes in 5% trichloroacetic acid, solubilization in 0.25 N NaOH, and scintillation 
counting. 
PAI-1 Western Blot Analysis. Stimulation of PAI-1 secretion into conditioned medium of BBE cells was 
assayed as described previously (32). BBE cells were treated for 18 h with conditioned medium from HCT116wt. 
HCT116vector, or medium from two different HCT11616K clones. Ten µl of BBE-conditioned medium were 
resolved by SDS-PAGE, transferred to a polyvinylidene difluoride membrane (Millipore) and immunoblotted 
with an anti-bovine PAI-1 mouse monoclonal antibody (Life Technologies, Inc.) at a dilution of 1:2,000. 
Antigen-antibody complexes were detected with horseradish peroxidase-conjugated secondary antibody 
(Amersham) and ECL (Amersham). 
DNA Fragmentation Assay. BBE cells were cultured as described previously above and, after stimulation with 
conditioned medium, lysed for analysis with the Cell Death Detection Elisaplus (Roche, Indianapolis, IN) 
according to manufacturer's instructions. Levels of DNA fragmentation in BBE cells were expressed as a factor 
of enrichment, calculated by dividing the absorbance of a given sample by the absorbance of the corresponding 
10% BCS control. Three separate spectrophotometric measurements (A405nm/A490nm) were averaged, and the 
background value for the assay was subtracted from each of these averages. 
Purification of 16K hPRL Out of Conditioned Media. Conditioned medium from cloned HCT11616K cells 
grown in McCoys' 5A containing 2.5% FCS was collected, brought to 850 mM (NH4)2SO4, and incubated 
overnight at 4°C with phenyl Sepharose 6 Fast Flow low sub media (Pharmacia), 4 ml of resin/liter of medium. 
Resin was packed and washed with 850 mM (NH4)2SO4-20 mM ethanolamine (pH 8.3) at 1 ml/min. 
Chromatography was performed in 20 mM ethanolamine (pH 8.3), and 16K hPRL was eluted within a gradient 
of (NH4)2SO4 from 850 mM to 0. Fractions containing 16K hPRL were collected, dialyzed against 20 mM 
ethanolamine (pH 8.5) and loaded onto an anion exchange Hitrap Q column (Pharmacia). The 16K hPRL was 
eluted within a gradient of NaCl from 0 to 1 M. Fractions containing purified 16K hPRL were pooled, dialyzed 
against 20 mM ethanolamine (pH 8.5), and stored at -20°C 
Chick CAM Assay. On day 3 of development, fertilized chick embryos were removed from their shells and 
placed in plastic Petri dishes. On day 6, 5-mm discs of methylcellulose (0.5%; Sigma Chemical Co.) containing 
10 µg of recombinant purified protein and 2 µg of BSA were laid on the advancing edge of the chick CAM as 
described previously (33). After a 48-h exposure period to test substances, white India ink was injected into the 
chorioallantoic sac to enhance photographic visualization. Results were considered positive only if an avascular 
zone of 5 mm in diameter or greater was observed. 
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HCT116 Cell Proliferation Assay. Cell proliferation studies were performed in 12-well culture plates (Falcon) 
seeded with 10,000 wild-type, plasmid, or 16K hPRL transfected HCT116 cells/well. Cells were grown in 10% 
BCS-supplemented medium for 6 days. Cell number was assayed after 2, 4, and 6 days using a hemocytometer. 
Tumor Studies. Male Rag1-/- mice (10-12 weeks of age) were housed in a barrier facility, and cell injections 
were performed under a laminar flow cabinet. The T- and B-cell-deficient Rag1-/-  mouse used in our 
experiments was created by a targeted disruption of the V(D)J Rag1. This mutation resulted in loss of all of the 
cellular components of the immune system, making it less leaky than that of the scid or nude mouse (34). For 
inoculation, HCT116wt, HCT116vector, or HCT11616K cell suspensions were prepared in serum-free culture 
medium. Mice were anesthetized by Methoxyflurane (Schering-Plough Animal Health Corp., Union, NJ) 
inhalation, and 5 × 106 cells in 100 µl of medium were injected s.c. into the dorsal region. Four experiments with 
four separate HCT11616K clones were undertaken. In each separate, experiment mice were sacrificed on the same 
day. The mean length of the tumor studies was 28 days, varying by 9 days in the four experiments [experiment 1 
(clone 4) 20 days, experiment 2 (clone 10) 24 days, experiment 3 (clone 10.2) 27 days, and experiment 4 (clone 
22) 41 days]. The tumors were excised, weighed, and fixed in 4% paraformaldehyde (EMS, Fort Washington, 
PA). The liver, lungs, and kidneys were examined for metastases macroscopically, and microscopically after 
fixation and staining by H&E. 
Immunohistochemistry. Assessment of tumor vascularity was done on paraffin-embedded, 5-µm tissue sections 
using a primary polyclonal antihu-man antibody recognizing vWF (Dako, Carpinteria, CA) at a dilution of 
1:2000 in blocking solution containing TBS (pH 7.3) and 3% horse serum. Incubation with primary antibody 
was carried out at 4°C overnight, followed by incubation with a biotinylated goat antirabbit secondary antibody 
(Vector Laboratories), at a dilution of 1:200 for 30 min at room temperature. Positive staining for respective 
antigens was detected by substrate reaction with 3,3-diamino-benzidine substrate (Zymed Laboratories, Inc., 
South San Francisco, CA). Sections were counterstained with hematoxylin for 10 s, dehydrated, and mounted in 
Cytoseal 60 (Stephens Scientific, Riverdale, NJ). Intratumor mi-crovessel density was determined by first 
selecting vWF-positive vascular hot spots at low magnification (x20), systematically scanning the whole section. 
Number of individually stained microvessels in a defined area were counted as reported previously (35) at x100. 
Immunolocalization experiments were repeated three times on multiple sections and at different tumor depths 
(serially sectioning to every 10th section). Experiments included negative controls for determination of 
background staining, which was negligible. 
Statistical Analysis. All values are expressed as mean ± SD. Multiple comparisons between treatment 
conditions were assessed by one-way ANOVA, followed by a post hoc analysis with the Student-Newman-Keuls 
test. Statistical significance was defined as a value of P < 0.05. 
RESULTS 
Expression of 16K hPRL in HCT116 Colon Cancer Cells.  
We first evaluated expression of the antiangiogenic factor 16K hPRL after stable gene transfer into the human 
colon cancer cell line HCT116. The cells were transfected with the 16K hPRL expression vector (HCT11616K) or 
the expression vector alone (HCT116vector). All constructs conferred neomycin resistance, and stable clones were 
selected by resistance to G418. Expression of 16K hPRL by cloned HCT11616K cells was confirmed by Northern 
and Western analysis. Four different stable clones of HCT11616K cells were shown to contain a transcript of 
expected size (624 bp; Fig. 1A), whereas the controls, HCT116wt and HCT116vector cells, contained no 16K hPRL 
transcript. The level of rnRNA expression varied among the different clones of HCT11616K cells. 
The Western blot analysis with a polyclonal anti-PRL antibody recognizing 16K hPRL in conditioned medium 
from HCT11616K cells demonstrated the presence of proteins of expected Mr 16,000 size (Fig. 1B). In addition to 
confirming the correct size of 16K hPRL expressed by HCT11616K cells, we used a RIA specific for 16K hPRL 
to determine the amount of 16K hPRL secreted into the conditioned medium. The magnitude of 16K hPRL 
secreted in 24 h into the medium by four different clones of HCT11616K cells ranged from 0.2 to 1 µg/ml. Our 
previous data showed that recombinant 16K hPRL inhibits mitogen-stimulated proliferation of BBE cells with an 
EC50 of 1-2 nM (6). The amount of 16K hPRL secreted into the conditioned medium by the lowest producing 
HCT11616K clone (c4) therefore exceeded 1 nM, whereas the highest producing clone (c10) secreted 16K hPRL 
at a rate 50 times greater than necessary for biological activity. 
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Biological Activity of HCT11616K Cell Conditioned Medium.  
We next asked whether the conditioned medium obtained from stably transfected HCT11616K cells contained 
biologically active 16K hPRL. Three different assays established in our laboratory for measuring 16K hPRL 
activity were used to test this biological activity: inhibition of BBE cell proliferation (5); stimulation of PAI-1 
expression (28); and activation of apoptosis in both BBE and human umbilical vein endothelial cells by 
measuring DNA fragmentation (21). 
As shown in Fig. 24, conditioned medium from HCT11616K cells inhibited bFGF-stimulated BBE cell 
proliferation in a dose-dependent fashion with an EC50 of 2.5 µl of conditioned medium from the highest 16K 
hPRL-producing clone (c10). Because the EC50 for recombinant 16K hPRL in this assay is 1 ΠM, there appears to 
be ~6.4 µg/ml of 16K hPRL in the conditioned medium, indicating that large amounts of biologically active 16K 
hPRL were secreted by clone 10 of the HCT11616K cells. Conditioned medium from HCT116wt cells had no 
effect on BBE cell growth, whereas conditioned medium from HCT116vector cells appeared to stimulate 
endothelial growth. 
Conditioned medium from two different HCT11616K clones (clones c4 and c10) stimulated production of PAI-1 
in BBE cells as measured by Western blot analysis (Fig. 2B). In contrast, conditioned medium from HCT116wt 
and HCT116vector cells (data not shown) had no effect on PAI-1 production. Because endotoxin is a known 
stimulator of PAI-1 (36), we ascertained that conditioned medium contained no significant endotoxin activity by 
preincubating the conditioned medium with PMB, an inhibitor of endotoxin activity. This had no effect on the 
stimulation of PAI-1 production by conditioned medium from HCT11616K cells. In addition, no endotoxin could 
be measured in the conditioned medium using the E-TOXATE (Limulus amebocyte ly-sate) assay. 
The level of DNA fragmentation, an early indicator of cells undergoing apoptosis, was determined after exposure 
to conditioned medium by measuring the cytosolic level of mono- and oligonucleosomes with an ELISA assay 
(21). Experiments were performed in BBE cells grown in low serum conditions (Control BBE, 0.5%) for 2 days, 
a treatment that caused a 2-fold increase in nucleosome formation compared with cells cultured in 10% BCS 
(Control BBE, 10%; Fig. 2C). Addition of 5 µl of conditioned medium from HCT11616K clones 4 and 10 to 
medium containing 0.5% BCS increased DNA fragmentation 4.7- and 3.2-fold compared with control medium 
(0.5% BCS), respectively. Conditioned medium from HCT116wt or HCT116vector cells had no effect. A 10 nM 
concentration of recombinant 16K hPRL increased DNA fragmentation 7.4-fold in BBE cells. Preincubation 
with PMB had no effect on the stimulation of DNA fragmentation by conditioned medium from HCT11616K cells 
or on the stimulation by 10 nΜ recombinant 16K hPRL. This demonstrated further that the conditioned medium 
contained no significant endotoxin activity. In contrast, heat denaturation of 16K hPRL by boiling the sample for 
2 min completely inhibited the stimulation of DNA fragmentation by both the recombinant 16K hPRL as well as 
conditioned medium from HCT11616K clones 4 and 10. In addition, 20 µl of conditioned medium from 
HCT11616K cells caused a 4-fold increase in nucleosome formation in human umbilical vein endothelial cells.       
A similar level of stimulation was observed with 5 nM recombinant 16K hPRL, confirming previously published 
results (23). No effect was observed with conditioned medium from HCT116wt or HCT116vector cells. 
Activity of Purified 16K hPRL from HCT11616K Cell Conditioned Medium.  
To further characterize the 16K hPRL secreted into the conditioned medium by the HCT11616K cells, it was 
purified by hydrophobic interaction on a phenyl Sepharose column. The eluted product comigrated with 
recombinant 16K hPRL made in. Escherichia coli when examined by Western blot analysis (data not shown).  
To assess the integrity of the purified 16K hPRL, we determined its antiangiogenic activity in vitro with the BBE 
proliferation assay and in vivo with the CAM assay. 16K hPRL purified from conditioned medium of clone c4 
inhibited bFGF-stimulated BBE cell proliferation in a dose-dependent manner with an EC50 of 2 nM (Fig. 3A). 
Purified 16K hPRL was also active in vivo, because it inhibited capillary formation in the chick CAM assay (Fig. 
3B). Ten µg of 16K hPRL were able to inhibit capillary formation in the area of the CAM surrounding the disc 
containing the 16K hPRL, whereas no effect was observed in the BSA control (arrows indicate the edge of the 
disc). These findings were in agreement with earlier work with recombinant 16K hPRL made in E. coli (6, 22), 
and they further strengthen the conclusion that HCT11616K cells secrete biologically active 16K hPRL. 
Antitumoral Action of 16K hPRL.  
To use the HCT11616K cells in xenograph studies using immunodeficient Rag-1-/- mice, we first needed to 
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determine whether 16K hPRL had any direct effect on the proliferation rate of HCT116 cells in vitro. We 
showed that HCT11616K cells grew at the same rate in vitro as HCT116wt and HCT116vector cells (Fig. 44). Also, 
the addition of increasing concentrations of recombinant 16K hPRL to cultures of HCT116wt cells had no effect 
on the rate of cell proliferation (Fig. 4B). Therefore, 16K hPRL had no detectable direct effect on the growth of 
these tumor cells. This finding agrees with previous observations that 16K hPRL only affected the growth of 
vascular endothelial cells (5) and validated the use of these cells in xenograph studies in Rag1-/- mice. 
 To study the growth of HCT11616K colon cancer cells in Rag1-/-mice, we injected five million cells s.c. in the 
scapular region under methoxyflurane anesthesia. In vivo growth of four different stable clones of HCT11616K 
cells were compared with control HCT116wt and HCT116vector cells. The size of tumors formed by HCT11616K 
cells was dramatically inhibited by a mean of 63% in four separate experiments (P < 0.01) compared with 
tumors formed from HCT116wt and HCT116vector cells (Fig. 5). Each of the four experiments shown was 
performed with a different subclone of the HCT11616K cells to exclude the possibility that clonal variability 
contributed to the observed tumor growth inhibition. All established HCT11616K clones inhibited the growth of 
s.c. tumors, and no tumor metastasis to the liver or other tissues was observed in these experiments with any of 
the cells. 
After removal of the tumors, increased peripheral vascularity could be observed around the periphery of tumors 
formed from HCT116vector cells but not in tumors formed from the HCT11616K cells (Fig. 6/4). In addition, tumor 
surfaces viewed during the sectioning process showed an even greater macroscopic difference in vascularity. To 
assess the vessel density in hotspots of tumors formed from HCT11616K (clone 22) and HCT116vector cells, tumor 
sections were analyzed for microvessel density by immunostaining with an antibody to vWF. Ten random fields 
of vessel hot spots were evaluated per tumor at three different depths through each tumor. Fig. 6B shows data 
from one level in which intratumoral microvessel density was decreased by 46% by the expression of 16K 
hPRL. The mean level of inhibition at all three levels was 44%. These data support the conclusion that 16K 
hPRL inhibited tumor growth by decreasing the level of angiogenesis in the tumors. 
DISCUSSION 
These studies demonstrate clearly that the antiangiogenic factor, 16K hPRL, is capable of inhibiting tumor 
formation from HCT116 cells implanted in Rag1-/- mice. HCT116 cells were stably transfected with an 
expression vector expressing 16K hPRL. Conditioned medium from HCT11616K cells inhibited the stimulation of 
BBE cell proliferation by bFGF, increased PAI-1 expression, and increased DNA fragmentation in BBE cells. 
Furthermore, 16K hPRL purified from the conditioned medium was capable of inhibiting angiogenesis in the 
CAM assay. 
Therefore, a stably transfected human colon cancer cell line was capable of producing and secreting large 
amounts of biologically active 16K hPRL. Tumor growth from HCT11616K cells implanted in Rag1-/- mice was 
significantly inhibited. This antitumoral action of expressed 16K hPRL appeared to be a result of its 
antiangiogenic action, because microvascular density was inhibited in these tumors. 
 
Problems arising from the production of recombinant proteins in E. coli were circumvented by stably 
transfecting HCT116 cells with an expression vector for 16K hPRL. The creation of stably transfected cells was 
successfully used for the expression of other antiangiogenic factors including thrombospondin-2 in human A431 
squamous cell carcinoma cells (37) and angiostatin in murine T241 fibrosarcoma cells (38). 
Large amounts of biologically active 16K hPRL were secreted into the medium by HCT11616K cells (0.2-1 µg/ml 
in 24 h). These levels were sufficient to have strong antiangiogenic effects in all of the assays studied. To 
increase the rate of translation of the 16K hPRL mRNA, a Kozak consensus sequence was inserted prior to the 
translational start site. The signal peptide targeting the peptide to the secreted pathway was also included in the 
construct. 16K hPRL was predominantly secreted into the culture medium (>95%), which is consistent with the 
efficient secretion of endogenous prolactin into the circulation from the anterior pituitary. 
A major issue in studying antiangiogenic activity in vitro has been contamination of recombinant protein 
preparations made in E. coli with endotoxin. Endotoxin has a potent antiangiogenic activity in in vitro assays 
with endothelial cells. Recombinant proteins made in E. coli are contaminated to varying degrees with endotoxin 
that is present in large amounts in these Gram-negative bacteria. Endotoxin levels can be decreased to levels 
where the activity is negligible; however, the techniques used for the removal of the endotoxin can lead to 
Published in: Cancer Research (2001), vol. 61, iss. 19, pp. 7356-7362  Page7  
Status: Postprint (Author’s version) 
inactivation of the biological activity of the peptide. The problem with endotoxin contamination was 
circumvented by the use of a gene transfer technique. We found no evidence that the activity of 16K hPRL 
secreted from HCT11616K cells was caused by contamination with endotoxin. In addition, we have shown that 
even with recombinant 16K hPRL preparations made in E. coli that the antiangiogenic activity is not dependent 
on endotoxin contamination but is dependent on the presence of the 16K hPRL molecule (21). 
 
That the antitumoral action of 16K hPRL expression was attributable to the antiangiogenic activity of the 
molecule is supported by several observations. The 16K hPRL secreted by the HCT11616K cells was 
antiangiogenic both in vitro and in vivo. More importantly, the inhibition of tumor growth from HCT11616K cells 
was correlated with a 44% decrease in microvascular density. This is similar to the level of inhibition of tumor 
growth and vascular density with that observed with angiostatin expression in T241 fibrosarcoma cells (33). The 
antitumoral action of 16K hPRL did not appear to involve a direct effect on growth of the HCT116 cells, because 
recombinant 16K hPRL had no effect on the growth of cultured HCT116wt cells. Furthermore, HCT11616K cells 
grew in vitro at the same rate as HCT116wt and HCT116vector cells. 
These findings provide the rationale for performing further studies on the ability of 16K hPRL to inhibit the 
growth and metastasis of tumors formed from human colorectal cell lines in appropriate models. The current 
studies do not address the role of angiogenesis in metastasis, because metastasis is infrequently observed after 
s.c. implantation of tumor cells (39). 
In conclusion, these data demonstrate clearly that stably transfected HCT116 cells are capable of secreting 
biologically active 16K hPRL that inhibits growth of tumors formed from a human colorectal cell line. That 
human colon cancer cells can produce large amounts of biologically active 16K hPRL supports the use of gene 
transfer approaches with viral vectors to inhibit colorectal cancer growth and metastasis. 
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FIGURES 
Fig. 1: Expression of 16K hPRL-139 in HCT116 colon cancer cells. A, Northern blot analysis of mRNA extracted from 
HCT116wt and stable clones of HCT116vector and HCT11616K cells. 16K hPRL mRNA was detected as 624-bp transcripts in four HCT11616K 
subclones not present in mRNA of HCT116wt or HCT116vector cells. B, Western blot analysis with polyclonal anti-hPRL antibody recognizing 
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Fig. 2: Biological activity of 16K hPRL expressed by HCT11616κ cells. A, conditioned medium from HCT116wt, 
HCT116vector, or HCT11616κ cells were tested for the ability to inhibit the mitogenic action of bFGF in the BBE cell proliferation assay. Cell 
proliferation was estimated by the rate of incorporation of [3H]thymidine, as described in "Materials and Methods." Results are means of 
triplicate wells for one representative experiment; bars, SD. B, Western blot analysis for PAI-1 levels in BBE cells treated with conditioned 
medium ± PMB from HCT116wt and clones c4 and c10 of HCT11616K cells. BBE cells were treated for 18 h with conditioned medium 
followed by collection of culture medium, which was subjected to Western blot analysis using an anti-bovine PAI-1 monoclonal antibody. C, 
conditioned medium from HCT116wt, HCT116vector, and HCT11616K clones c4 and c10 were tested for effects on DNA fragmentation in BBE 
cells. Quiescent BBE cells were left untreated (Control BBE 10%), serum deprived (Control BBE 0.5%), or stimulated in 0.5% BCS with 5 
µl of conditioned medium from HCT116wt, HCT116vector or HCT11616κ cells. Ten nM recombinant 16K hPRL was used as a positive control. 
The same conditioned medium or recombinant 16K hPRL pretreated with PMB or boiled for 2 min was also tested. Data are means of three 
independent experiments; bars, SD 
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Fig. 3: Biological activity in vitro and in vivo of purified 16K hPRL from conditioned medium of HCT11616K cells. A, purified 16K hPRL 
from HCT11616K clone c4 inhibited the stimulation of BBE cell proliferation by bFGF in a dose-dependent fashion. Data are means of 
triplicate wells for a representative experiment; bars, SD. B, the same preparation of purified 16K hPRL inhibited capillary formation in the 
chick CAM assay, as described in "Materials and Methods." An area >5 mm in diameter devoid of capillaries was observed in three of four 
membranes surrounding the 16K hPRL (10 µg)-impregnated disc (arrow). No effect can be observed in the control in which the disc 
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Fig. 4: HCT116 cells are not affected by 16K hPRL expression. A, HCT11616K, HCT116wt and HCT116vector cells all grew at 
the same rate in culture. Growth rate of cells was monitored over a 6-day period by determining cell number of triplicate wells by 
hemocytometer (means; bars, SD). B, the addition of increasing concentrations of recombinant 16K hPRL had no effect on the rate of 
proliferation of HCT116wt cells as quantitated by [3H]thymidine incorporation. Data are means of triplicate wells; bars, SD 
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Fig. 5: Size of tumors formed from HCT11616K, HCT116wt, and HCT116vector cells injected s.c. in Rag1-/- mice, as described in "Materials 
and Methods." Significant decrease in weight of HCT11616K tumors compared with HCT116wt and HCT116vector tumors (*, P < 0.01). Four 
separate experiments with different subclones of stable HCT11616k cells are shown (upper left corner, clone number). Data are means; bars, 
SD The number of animals per group is indicated in parentheses at the bottom of each column 
 
Fig. 6: A, digital scanning of tumor surfaces from tumors formed by s.c. injection of HCT11616K (clone 22) and HCT116vector cells in Rag1-/- 
mice (lower right panel, respective tumor sizes). Increased peripheral vascularity and hemorrhagic areas can be observed in the tumors 
formed from HCT116vector cells but not from tumors formed from HCT11616K clone c22. B, decrease in mean microvessel density in tumors 
formed by HCT11616K compared with HCT116vector cells (*, P < 0.001). Number of tumor vessels immunostained with an antibody to vWF 
were counted in 10 random fields of vascular hotspots in each tumor section at x100. Data are means of vWF-positive vessel in tumor 
sections from HCT116vector and HCT11616K cells (n = 50); bars, SD 
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